Description: This report is a discussion of the significant challenges involved in attempting to research with robust analysis the impact of disparities in health care access, cost and quality of care on financial wellness across racial, ethnic, socioeconomic and other demographic groups in the U.S. for reasons other than or in addition to income, wealth or employment status.

Description: The SOA Research Institute along with the International Section, and the Social Insurance and Public Finance Section are pleased to make available a research report that compares international and domestic mandated paid family and medical leave programs. Special thanks to both Sections for their sponsorship of this effort.

Description: Update from the life insurance industry trade's perspective on tax policy and political issues

Description: The SOA Research Institute’s Aging and Retirement Strategic Research Program and Canadian Institute of Actuaries are pleased to make available the first of two reports that look at Benefit at Risk (BaR) in lifetime pension pools.

Description: Guidance and a model for actuaries to use when performing their professional services related to Medicaid (Title XIX) and Children’s Health Insurance Program (CHIP or Title XXI) managed care capitation rate setting.

Description: Investigate the importance of collaboration with accounting, underwriting, sales, marketing and other professions as an actuary when you attend this webcast. Cross-functional positions can cause unique challenges to arise, like various experts attempting to balance growth and profitability. Discover an opportunity to learn about relevant ASOPs and dive deeper into contemporary examples that highlight specific professionalism issues that can develop.

Description: Develop a better understanding of specialty drug trends and their increasing healthcare costs for more than the past decade by attending this webcast. With the introduction of price competition, you will see changes in the market for biosimilar products and patent-protected drugs. For example, the drug Humira will be gaining 10 biosimilar competitors in 2023. Alone, Humira can represent over 20% of total pharmacy spend for health plans. Join us and discover how price competition is a turning point for the pharmaceutical industry and will define its direction for the next decade.

Description: Join us for an insightful webcast as we delve into the far-reaching implications of the recent Supreme Court decision to overturn Chevron deference. This landmark ruling, which previously granted federal agencies significant leeway in interpreting ambiguous statutes, is set to reshape the landscape of healthcare policy.

Description: The editor of Health Watch previews the articles in this issue.

Description: In September 2017, the China Insurance Regulatory Commission (CIRC) issued the “C-ROSS Phase II project construction plan”, planned to be used across three years’ time, by perfecting the regulations, improving the operational mechanism and strengthening the regulatory cooperation.